Introduction & Objective: CGM use has been shown to improve glycemic outcomes in people with diabetes. We investigated CGM use pre- and post-initiation of GLP-1 or GIP/GLP-1 RA (incretin) therapy in a T2D cohort using real world data.
Methods: Retrospective analyses of electronic health records were conducted using Truveta data. People with T2D aged ≥30 years initiating incretin therapy were evaluated from 2018-2022 in 3 cohorts: intensive-insulin treated (IIT), basal-insulin treated (BIT) and non-insulin treated (NIT). CGM use was assessed 12-months pre- and post-incretin therapy initiation.
Results: Overall the cohort (n=299,157) was: 64.9-67.8% White, 52.1-53.8% female, mean (SD) 57.3 (11.7) to 59.5 (12.4) years of age. Over 5 years, individuals initiating incretin therapy approximately doubled in the insulin-treated cohorts (IIT=99%, BIT=85%) with a nearly 250% increase in the NIT cohort. CGM use increased each year pre- and post-incretin therapy initiation, with larger proportions observed in the insulin-treated cohorts vs NIT (Table).
Conclusion: These findings indicate that CGM use in people with T2D has increased substantially over 5 years, with a greater relative proportion of CGM use post- vs pre-incretin therapy initiation, independent of insulin use. Future research will evaluate the potential benefits of CGM use in conjunction with incretin therapy to optimize glycemic outcomes in people with T2D.
X. Wang: Employee; Dexcom, Inc. Y. Xu: Employee; Dexcom, Inc. G.J. Norman: Employee; Dexcom, Inc. J.L. Reid: Employee; Dexcom, Inc. H. Singh: Employee; Dexcom, Inc. L. Yang: Employee; Dexcom, Inc.
